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Background: Most people exposed to M. tuberculosis show no evidence of clinical disease. Five to 10% of
individuals with latent infection progress to develop overt disease during their life time. Identification of people
with latent TB infection will increase case detection rates and may dictate new treatment policies to control
tuberculosis. This study aimed to determine LTBI point prevalence in a population from Sudan using two different
diagnostic methods: the tuberculin skin test (TST) and the IFN-γ release assay (IGRA).
Methods: This was a prospective, community-based and case-controlled study. Following informed consent,
household contacts (HHCs; n = 98) of smear-positive index cases and Community controls (CCs; 186), were enrolled.
Tuberculin skin test (TST), whole blood stimulation with ESAT-6/CFP-10 ± TB7.7 antigens or purified protein
derivative (PPD) and IFN-γ levels determination with ELISA were performed. The levels of IFN-γ and TST induration
between the CCs and the HHCs were compared using student t-test, Chi-square and Kappa coefficient. Pearson
correlation test was used to compare TST and IFN-γ. P levels of <0.05 were considered significant.
Results: TST induration of≥ 10 mm gave an LTBI point prevalence of 327 cases/1000 individuals among HHCs
compared to 126 cases/1000 individuals among CCs (p = 0.000). PPD-induced IFN-γ release assay gave an LTBI point
prevalence of 418 cases/1000 individuals among HHCs compared to 301 cases/1000 individuals among CCs
(p =0.06). On the other hand ESAT-6/CFP-10 ± TB7.7-induced IFN-γ gave an LTBI point prevalence of 429 cases/1000
individuals among HHCs compared to 268 cases/1000 individuals among CCs (p = 0.01). IFN-γ productions levels
induced by ESAT-6/CPF-10 ± TB7.7 antigens in HHCS and CCs were not significantly different from those induced by
PPD (p = 0.7).
Conclusion: IFN-γ release assay (IGRA) gave higher LTBI point prevalence compared to TST in HHCs and CCs. PPD
gave comparable results to ESAT-6/CFP-10 ± TB7.7 antigens in whole blood IFN-γ release, making it a cheap
alternative to the recombinant antigens.
Keywords: Latent Tb infection, IFN-γ release assay, TST, Sudan, Contact tracing* Correspondence: eltahirgasim@yahoo.ca
2Department of Clinical Pathology & Immunology, Institute of Endemic
Diseases, University of Khartoum, Medical Campus, Qasr Avenue, P.O. Box
45235, Postal code 11111, Khartoum, Sudan
7Central Laboratory, Ministry of Science & Communications, Khartoum, Sudan
Full list of author information is available at the end of the article
© 2013 Shakak et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Shakak et al. BMC Public Health 2013, 13:1128 Page 2 of 6
http://www.biomedcentral.com/1471-2458/13/1128Background
Tuberculosis (TB) is a contagious and airborne disease
of poverty that mostly affects young adults in their most
productive years in developing countries. The vast ma-
jority of TB deaths are in the developing world with an
estimated two million deaths annually. WHO reported
that one third of the world population is infected with
latent TB with 9.4 million new overt cases annually [1].
Five to 10% of individuals with latent TB progress to de-
velop overt disease during their life time. Identification
of people with latent TB infection (LTBI) will increase
case detection rates and may dictate new treatment pol-
icies to control tuberculosis. In the absence of a gold
standard test for identification of individuals with LTBI,
different reports suggested tuberculin skin test (TST) or
interferon-γ release assay (IGRA) as the best test [2-7].
The tuberculin skin test (TST) remains the most com-
monly used test for diagnosing latent TB infection
(LTBI) that could indicate preventive treatment [2]. TST
has a number of limitations: low sensitivity in immune-
compromised patients and cross-reactivity with hyper-
sensitivity in BCG-vaccinated and non-tuberculous
mycobacterial (NTM) infections [3]. Recently a new
diagnostic test IFN-γ release assay (IGRA) which mea-
sures the production of IFN-γ in whole blood upon
stimulation with specific antigens has been introduced.
These antigens (Early Secreted Antigenic Target-6;
ESAT-6 and Culture Filtrate Protein-10; CFP-10),
though unique to M. tuberculosis in the latent state, have
been found in some non-tuberculous Mycobacteria and
M. leprae. IFN-γ produced by T-cells plays a critical role
in protective immunological responses to primary infec-
tion. The QuantiFERON-TB Gold In-Tube (QFT-GIT;
Cellestis Ltd. Carnegie, Victoria, Australia) is the newest
IGRA assay. In addition to the ESAT-6 and CFP-10 pep-
tides, this test utilizes the TB7.7-M. tuberculosis specific
peptide as well. Unfortunately, IGRAs cannot differenti-
ate between active and past TB infections or between
LTBI and tuberculosis [4-6].
This study aimed to determine LTBI point prevalence
in a Sudanese population using TST and the IFN-γ re-
lease assay. The study also aimed to compare PPD and
ESAT-6/CPF-10 ± TB7.7 antigens as stimulants for IFN-
γ release in whole blood stimulation in vivo systems.
Methods
Scientific and ethical considerations
The study was approved and passed by the Ethics & Sci-
entific Committees of the Institute of Endemic Diseases,
University of Khartoum and the Ethics Committees of
the Federal Ministry of Health, Khartoum. Written in-
formed consents were obtained from all participating in-
dividuals. The national TB control program was heavily
involved from the start of the study.Study population
Index cases with smear-positive sputum pulmonary TB
and at least one household contact were initially en-
rolled. House hold contacts (HHCs) of these cases were
recruited based on the following inclusion criteria:
age ≥15 years, living for more than six months at the
same property as the respective index case, agreeing to
participate and they/their guardian sign the informed
consent. Sex-matched Community controls (CCs) were
enrolled if: age ≥15 years, have no history of tuberculosis
in his/her household, have no symptoms/signs of tuber-
culosis and has signed an informed consent.
Tuberculin skin testing
Tuberculin skin test (TST) was performed on all con-
tacts by the administering 0.1 ml containing 5 tuberculin
units (Razi Institute, Iran). Transverse induration was
measured 72 hours later using the ballpoint pen tech-
nique. A reaction equal or more than 5 mm was consid-
ered as reactive [8].
Whole blood stimulation and IFN-γ release assay
For one hundred individuals whole blood stimulation
and measurement of IFN-γ levels was conducted using
QFT-G- in Tube Kit (Cellestis Ltd., Victoria, Australia)
as per manufacturer’ instructions. Due to interruption of
Kits supplies, M. tuberculosis recombinant antigens
(ESAT-6/CFP-10, Cellestis Ltd., Victoria, Australia) and
PPD were used in the rest of the volunteers (184 CCs),
while IFN-γ production assay was performed using
ELISA Kits from Komabiotech, Seoul, South Korea as
per manufacturer’ instructions. The IFN-γ measurement
kits were validated and compared at the QC Unit of the
Institute of Endemic Diseases, University of Khartoum.
Whole blood stimulation was performed as follows: one
ml of blood was taken in each of four tubes: 1. ESAT-6/
CFP-10 antigens 2. Phytohemagglutinin (PHA) for the
positive control 3. No antigen for the negative control 4.
Five PPD antigen units. The tubes were incubated for
24 hours at 37°C in Cellestis incubator (Cellestis Ltd.,
Victoria, Australia), and plasma was collected after cen-
trifugation and stored at −20°C until assayed. A cut-off
of 0.35 IU/mL for IFN-γ was applied.
Statistical analysis
Statistical analyses were performed using Epidemio-
logical Information (Epi Info) software version 3.4.3.0.
The levels of IFN-γ cytokine and TST induration be-
tween the CCs and the HHCs were compared using stu-
dent t-test and Chi-square. Pearson correlation test was
used to compare TST and IFN-γ. P levels of <0.05 were
considered significant. Kappa coefficient of agreement
between TST and IGRA; PPD-induced IFN-γ release and
ESAT-6/CFP-10 ± TB7.7-induced IFN-γ release for the
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previously [9].
Results
A total of 284 consenting volunteers were enrolled in
the study, ninety eight were House-Hold Contacts
(HHCs) for 25 Index Cases and 186 were Community
controls (CCs) with a male: female ratio of 1:4. The
mean age of HHCs was 30 ± 11.0 years and that of CCs
was 29 ± 10.0 years. Females were predominant in both
HHCs and CCs, where they were four times more than
males. All volunteers had history of BCG vaccination
that was confirmed in the majority (>85%) by presence
of a scar. TST induration and positivity were signifi-
cantly different in HHCs compared to CCs (p = 0,000)
(Table 1). Sixty per cent of HHCs had TST induration
of <5 mm compared to 83% in CCs. Volunteers with
TST induration of ≥10 mm were seen more frequent
among HHCs (25.5%) compared to CCs (9%). Volun-
teers with TST of ≥ 15 mm were mainly seen in house
hold contacts (p = 000). Nineteen of CCs could not be
traced for TST reading in screening (Table 1).
The mean IFN-γ production level for the ESAT-6/
CFP-10 ± TB7.7 whole blood stimulation was signifi-
cantly different for the HHCs (0.5 ± 0.7 IU/ml) com-
pared to the CCs (0.2 ± 0.2 IU/ml) (p = 0.000). These
recombinant antigens stimulation gave IFN-γ production




TST (mean ± SD) 5 ±6
< 5 mm 59 (60.2%)
5 - 9 mm 12 (12.2%)
10 - 14 mm 13 (13.2%)§
≥ 15 mm 14 (14.4%)§
IFN-γ Mean level IU/ml:
Purified Protein Derivative:
Mean ± SD 0.5 ± 0.6
< 0.35 57/98 (58.2%)
0.35-1.0 28/98 (28.6%)
1.1-2.0 13/98 (13.2%)
ESAT-6 + CFP −10 ± TB7•7:
Mean ± SD 0.5 ± 0.7
< 0.35 56/98 (57.1%)
0.35 - 1.0 18/98 (18.4%)§
1.1 - 2.0 24/98 (24.5%)§
Continuous variable are expressed as means ± SD. *Significant difference (p < 0.05).
§There was a low correlation between IFN-γ level >0.35 IU/ml and TST ≥10 mm (r =
All volunteers had history of BCG vaccination that was confirmed in the majority (>compared to 26.9% (50/186) of CCs (p = 0.01) only in
the 0,35-1,0 range. Fifty seven percent of the HHCs were
not reactive in whole blood IFN-γ production compared
to more than seventy percent in the CCs (p = 0.03). In
PPD-whole blood stimulation, IFN-γ production levels
of ≥ 0.35 IU/ml were 41.8% (41/98) and 30.1% (56/186)
for HHCs and CCs respectively (p = 0.06 not significant).
IFN-γ productions levels induced by ESAT-6/CPF-10 ±
TB7•7 antigens were not significantly different from those
produced by PPD in HHCs and CCs (p = 0.7). Kappa co-
efficient of agreement between PPD-induced IFN-γ release
and ESAT-6/CFP-10 ± TB7.7-induced IFN-γ release for the
study population was calculated at 1 (Table 1).
No correlation between TST and IFN-γ production levels
in HHCs and CCs could be detected (r = 0.4).
TST induration of ≥ 10 mm gave a LTBI a point
prevalence of 327 cases/1000 individuals among HHCs
compared to 126 cases/1000 individuals among CCs
(p = 0.000). PPD-induced IFN-γ release assay gave an
LTBI point prevalence of 418 cases/1000 individuals
among HHCs compared to 301 cases/1000 individuals
among CCs (p =0.06). On the other hand ESAT-6/
CFP-10 ± TB7.7-induced IFN-γ gave an LTBI point
prevalence of 429 cases/1000 individuals among HHCs
compared to 268 cases/1000 individuals among CCs
(p = 0.01). Overall, LTBI point prevalence was calcu-
lated in the study population for TST (induration ≥
10 mm), PPD-IFN-γ induced and ESAT-6/CPF-10 ±whole blood cultures [ESAT-6/CFP-10 & PPD] in the study
















85%) by presence of a scar. **Nineteen CCs did not report for TST reading.
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spectively (Table 1).
The Cohen’s co-efficient of agreement between TST
and IGRA for the study population was calculated
at 0.52.
Discussion
Tuberculosis control programs in developing countries
are greatly haunted by low case detection rates and la-
tent TB infections that constitute hidden pools that con-
tinuously feed new cases. Accurate diagnosis of LTBI
and appropriate treatment of probable cases-to-be re-
duce the risk of progression to overt disease and in-
crease case detection rates [7,10]. However the role of
preventive treatment in high burden countries needs to
be assessed. Furthermore, testing of adult contacts is
controversial in high incidence countries [11]. At present
time there is no gold standard test for the detection of
individuals with LTBI and TST has been the most widely
used diagnostic tool in the detection of LTBI for more
than a century. TST is a simple and cheap test but has
reduced specificity as BCG vaccination may affect the
results as in our population. TST is an in vivo test that
measures skin induration response due to cytokines/che-
mokines secretion (IL- 4, IFN-γ, tumor necrosis factor-α,
IL-10, IL-12 and G-CSF) [2]. On the other hand, whole
blood IFN-γ release assays are highly specific for latent
M. tuberculosis, but are expensive, need special equip-
ment and expertise and are not widely available in devel-
oping countries. In addition, these tests have limited
predictive values to identify those patients who will de-
velop overt tuberculosis [12-23]. IFN-γ release assay
(IGRAs) measure only IFN-γ production, a T helper 1
response, so it remains possible that positive TST results
might capture an immune response in truly infected in-
dividuals that are missed by the IFN-γ release assay [14].
In the absence of a gold standard test for LTBI, we took
LTBI point prevalence as an objective measure of LTBI. In
our study, IFN-γ release assays were more frequently posi-
tive in HHCs than the TST, a result that may indicate a bet-
ter sensitivity. These data are in agreement with previous
studies that reported that IFN-γ release assay is better than
TST in detecting individuals with LTBI [12-22]. Lowering
the TST induration to ≥ 5 mm gave an LBTI point preva-
lence that is comparable to IFN-γ release assay test in pre-
vious reports [20-22].
Low correlation between TST and IFN-γ release assay
has been reported in this study as well as in many other
studies [19,21,22]. On the other hand, many other studies
have reported moderate to strong positive correlation be-
tween the TST and IFN-γ release assay tests. These later
studies presented TST as the least cost-effective, while
others reported that TST followed by IGRA as highly cost
effective [22,24-26]. It is worth mentioning that a studyfrom South Africa suggested that TST was more effective
in identifying LTBI than three generations of a whole blood
IFN-γ release assay tests in countries with high TB burden
[27]. Park and colleagues found that the cost effectiveness
of the different testing strategies for LTBI was very variable
especially between tests reagents [28]. The cost of QFT
(IGRA) per person was reported to be between $20 and
$30, while that of TST was ~ $5. In our setting, the cost of
the TST process and IGRA were calculated at around $2
and $20 respectively, cheaper than that reported elsewhere.
The cost of individuals having to come back for TST read-
ing can easily be offset by the comparatively high cost of
the IGRA tests. TST and IGRA were shown to have moder-
ate agreement in the study population, presenting it as a
cheaper alternative when cost constitutes a limitation for
TB control programs in developing countries [29,30].
This study showed that IGRA positivity and TST re-
activity were associated with close exposure to index
cases (IC) as evidenced by the significant differences in
reactivity of IFN-γ release tests/TST among HHCs and
CCs. These results are concordant with previous reports.
The low prevalence of LTBI among CCs probably indi-
cates lower than national average prevalence of TB in
the study area. Sudan is a vast country and prevalence
rates vary considerably between different counties [1].
In the absence of a gold standard test for the diagnosis
of LTBI, developing countries with high burden of TB
have been relying on TST to diagnose LTBI especially in
children, where treatment of LTBI diagnosed by TST
has been shown to reduce the risk of progression to ac-
tive TB by 60-90% [31,32].
In this study IFN-γ release test results gave a high
LTBI point prevalence that is comparable to that re-
ported from India and Ethiopia [33,34].
Purified Protein Derivative (PPD) gave similar results
to ESAT-6/CFP-10 ± TB7.7 in whole blood IFN-γ release
assay, with an almost perfect degree of agreement, mak-
ing it a cheap alternative to recombinant antigens. This
is in concordance with previous reports by Brock and
colleagues [32] where they reported comparable levels of
sensitivities for the QuantiFERON-TB test based on M.
tuberculosis-PPD and that based on ESAT-6 or CFP-10
antigens. These findings can markedly reduce the high
cost of IFN-γ-release assay tests. However we didn’t find
a significant difference in terms of PPD IFN-γ whole
blood assays levels between HHCs and CCs, which may
imply a significant overlap between the values in these
BCG-vaccinated populations due to lower specificity of
PPD.
Conclusion
IFN-γ release assay (IGRA) using PPD or ESAT-6/CFP-
10 give higher LTBI point prevalence compared to TST,
which may indicate better sensitivity but the high cost of
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Although a less specific test, Purified Protein Derivative
(PPD) gave comparable results to ESAT-6/CFP-10 ±
TB7.7 in whole blood IFN-γ release assay, making it a
cheap alternative to recombinant antigens.
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